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Summary
Introduction: Incubation of blood with CrSO4-coated glass beads stimulates the synthesis of anti-inﬂammatory cytokines, such as interleukin-1
receptor antagonist (IL-1ra), IL-4, IL-10, and IL-13. As IL-1b is thought to play a key role in the development of osteoarthritis (OA), this product,
also known as Orthokin, might be a viable treatment for symptomatic knee OA. The aim of the current study was to evaluate the efﬁcacy of
Orthokin for treatment of symptomatic knee OA in a randomized, multicentre, double-blind, placebo-controlled trial.
Patients and methods: One hundred and sixty-seven patients received six intra-articular injections either with Orthokin or physiological saline.
The primary efﬁcacy objective consisted of 30% superiority on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
at 3, 6, 9, and 12 months post-treatment. Additionally, the patients completed the visual analogue scale for pain, the Knee injury and Osteo-
arthritis Outcome Score (KOOS) and Knee Society Clinical Rating System.
Results: Orthokin and placebo treatment resulted in similar improvements on the WOMAC (16.8% vs 16.5%, respectively; n.s.). Orthokin re-
sulted in signiﬁcantly more improvement for KOOS symptom (P ¼ 0.002) and KOOS sport (P ¼ 0.042) parameters as compared to placebo
treatment. For most other outcome parameters, Orthokin-treated patients consistently showed higher improvement compared to placebo-
treated patients, although none of these differences were statistically signiﬁcant. Two serious adverse events were observed in the Orthokin
group: one patient with repeated severe inﬂammatory reactions of the knee joint within hours after the injection and one patient with septic
arthritis which was attributed to the injection procedure rather than the product.
Conclusion: The statistically signiﬁcant improvement of KOOS symptom and sport parameters together with the consistently higher, though
non-statistically signiﬁcant, improvement of most other parameters demonstrates that Orthokin clearly induces a biological response different
from placebo treatment and warrant future investigations into the possible chondroprotective effect of Orthokin. However, in the current study
the primary efﬁcacy objective was not met and, therefore, the use of Orthokin currently cannot yet be recommended for the treatment of OA.
ª 2007 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Biological joint reconstruction is a viable and realistic goal in
regenerative medicine. Altering the joint homeostasis, i.e.,
factors that determine the intra-articular environment, can
be an important pathway by which we may improve treat-
ment of OA and cartilage defects.
Osteoarthritis (OA) is a slowly progressive, degenerative,
and disabling disease of articulating joints that not only
affects the elderly, but also involves younger, more active*Address correspondence and reprint requests to: D. B. F. Saris,
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498patients, e.g., post-traumatic or due to prolonged participa-
tion in high demanding sports1e4. Treatment of this young
population is especially troublesome as current treatment
options, such as nonsteroidal anti-inﬂammatory drugs
(NSAIDs) and cyclooxygenase-2 (COX-2) inhibitors, do
not prevent the progression of OA, although they have
been proven to effectively reduce symptoms of OA5,6. In ad-
dition, prolonged use of these drugs is related to important
drawbacks, such as increased risk of upper gastrointestinal
bleeding and cardiovascular ischaemia through platelet
activation7e10.
Over the last two decades, OA research has increasingly
focussed on drugs that not only improve the patients’ symp-
toms, but additionally are capable of altering the course of
OA development and consequently postpone or even
prevent the need for total joint replacement, the so-called
499Osteoarthritis and Cartilage Vol. 16, No. 4disease modifying osteoarthritis drugs (DMOADs). Best
known are glucosamine and chondroitin sulphate. When
used in combination, these have recently demonstrated to
be effective in reducing clinical symptoms in a subgroup
of patients with moderate-to-severe knee pain11. However,
whether glucosamine and chondroitin sulphate are effective
modiﬁers of OA progression is still controversial, although
some studies suggest that these substances may inhibit
the radiographic progression of OA12,13. In addition, the
mechanism through which these substances should alter
the course of OA development remains unclear, although
recent studies have suggested a chondroprotective effect
through inhibition of the expression of matrix degrading
enzymes such as MMP-1314.
A viable target for DMOADs are pro- and anti-inﬂamma-
tory cytokines, as these are known to be involved in OA
development15e20. Of these, interleukin-1b (IL-1b), a pro-
inﬂammatory cytokine, has been proposed to play a key
role21e23. It induces the production of collagenase and pros-
taglandin and results in decreased synthesis of cartilage
speciﬁc collagens and proteoglycans19,24e26. In an experi-
mental equine OA model, in vivo delivery of the IL-1Ra
gene results in signiﬁcant improvement in clinical parame-
ters of pain and disease activity, preservation of articular
cartilage, and beneﬁcial effects on histological parameters
of the synovial membrane and adjacent articular cartilage27.
Orthokin (Orthogen, Du¨sseldorf, Germany) is a product in
which whole blood is incubated with CrSO4-coated glass
beads. This process has been demonstrated to stimulate
the synthesis of IL-1 receptor antagonist (IL-1ra) and other
anti-inﬂammatory cytokines, such as IL-4, IL-10, and
IL-1328. Therefore, Orthokin might have a beneﬁcial effect
on the symptoms and disease progression of OA. The aim
of this study is to investigate the efﬁcacy of this from of au-
tologous IL-1ra for the relief of symptoms in patients with
OA of the knee in a prospective, randomized, double-blind,
placebo-controlled study of intra-articular injection therapy.Materials and methods
A prospective double-blind placebo-controlled randomized multi-centre
trial was conducted to evaluate the efﬁcacy of intra-articularly injected Ortho-
kin vs placebo (physiological saline) in reducing symptoms of OA in the
knee. This trial was conducted over a period of 30 months; the ﬁrst patient
was included in February 2004 and the last patient completed follow-up in
August 2006. The trial was performed at seven centres in the Netherlands
and was approved by medical ethics comity of the University Medical Center
in Utrecht and the local ethics committee at each participating study site.PATIENTSEligible patients were aged >18 years and had clinical evidence of OA as
judged by the orthopaedic surgeon, deﬁned by the presence of typical knee
symptoms (pain, stiffness, disability) and radiographic evidence of OA
(grades IeIII on the KellgreneLawrence index). Other inclusion criteria
were knee complaints surpassing the threshold indicated by at least two of
the following questionnaires: maximal 60 points out of 100 points on the
Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC),
the pain sub-item of the Knee injury and Osteoarthritis Outcome Score
(KOOS), or the Knee Society clinical rating scale (KSCRS), and minimal
40 mm for the 100-mm Visual Analogue Scale (VAS) for pain.
Exclusion criteria were poor general health as judged by the orthopaedic
surgeon; concomitant painful or disabling disease of the spine, hips, or lower
limbs that would interfere with evaluation of the afﬂicted knee; suspicion of ip-
silateral coxarthrosis and hip prosthesis loosening; any clinically signiﬁcant or
symptomatic vascular or neurological disorder of the lower extremities; crystal-
line, inﬂammatory and infectious arthropathies, known human immunodeﬁ-
ciency virus (HIV), hepatitis, cytomegalovirus or syphilis infections, current
diagnosis of osteomyelitis, alcohol/drug abuse, OA grade IV; known immuno-
deﬁciency; participation in other trials within 3months of inclusion, surgical and
intra-articular pharmacological treatment within 6 months of inclusion, known
coagulopathy; corticosteroid and anti-coagulant usage or morbid obesity.RANDOMIZATIONAll participants were enrolled between February 2004 and August 2005.
They were ﬁrst seen in the practice of their orthopaedic surgeon, who evalu-
ated eligibility for enrolment based on in- and exclusion criteria. Furthermore,
the patients received a written information brochure and were informed ver-
bally after which the patients were given at least 24 h to consider participation
in the trial. Subsequently, all patients were seen by a specially trained local
study physician, who provided information concerning the trial, the products,
and the alternatives, and obtained written informed consent. Next, in order to
assess whether the participants met all inclusion criteria, the patients com-
pleted all questionnaires and x-rays (weight-bearing antero-posterior, so-
called notch view, weight-bearing lateral, and patellar skyline) were obtained.
If the participants still met all in- and exclusion criteria, they were randomized.
Therefore, a computer-generated randomization code was produced accord-
ing to the ‘‘random-permuted-block within strata principle’’ by a researcher
not afﬁliatedwith the trial using SYSTAT for windows (SYSTAT Inc., Evanston,
IL,USA). The randomizationwas stratiﬁed for gender, age (<45and>45 years
of age) and NSAID usage, i.e., a separate randomization scheme was gener-
ated for each stratum separately. In cases of severe subjective symptoms, pa-
tients were able to indicate whether NSAID usage would be continued during
the trial. The randomization code was managed by a trial coordinator, who al-
lotted the participants either to theOrthokin of the placebogroup in a sequential
manner according to the randomization code. The participants and their ortho-
paedic surgeon were blinded for the treatment to which the patients were as-
signed throughout the study.
One knee per patient was analysed. Patients who needed bilateral treat-
ment were randomized as described above and were treated with the same
product in both knees. However, since two knees in the same patient cannot
be analysed statistically as independent specimens, an additional randomi-
zation step was performed to determine which knee would be analysed by
using a randomization scheme that was also generated using a random per-
muted block design.
Patients were informed that all placebo group patients would be given the
opportunity to have the Orthokin treatment if effectiveness was determined at
completion of the trial.INTERVENTIONAfter randomization, all participants returned to the local study physician,
where 50 ml of venous blood was obtained using the Orthokin syringe, which
contains the CrSO4-coated glass beads. The syringe was gently rotated to en-
sure complete mixing and maximal contact of beads and blood, immediately
stored at 37C and shipped to the Orthogen laboratory within 24 h in a desig-
nated transport incubator. At the laboratory, the blood samples were tested
for Hepatitis A and B, and HIV because of uncertainty of virus titre response
to such incubation. If blood samples were found positive for one of these dis-
eases, the patients were retested using new blood samples. In case of re-
peated positive test-outcome, the patients were excluded from the study.
When the patient was tested negative, the Orthokin product was prepared by
the Orthogen laboratory and was returned to the hospital after 14e21 days
in 2-ml vials at 20C. Subsequently, an injection regime of six injections
was started in a rigid scheme comprising 3 weeks: injections were given on
day 0, 3, 7, 10, 14 and 21. The participant was placed in a supine position,
the knee was disinfected with alcohol draped in a sterile fashion. A sterile
21-gauge needle was placed supero-laterally into the supra-patellar pouch.
The synovial ﬂuid present was aspirated to minimize drug dilution. The needle
was left in place and 2 ml of Orthokin or 2 ml of placebo (physiological saline)
was injected through a 0.22-mm pore size anti-bacterial sterile ﬁlter. All proce-
dures were identical for both the Orthokin and the placebo injections.FOLLOW-UPAt 3, 6, 9 and 12 months after the ﬁrst injection, the patients completed the
same questionnaires as at baseline, namely the VAS for pain, the KOOS and
the KSCRS. The WOMAC scores were deducted from the separate KOOS
items. All questionnaires were sent by mail and were completed prior to
the follow-up visits with the treating orthopaedic surgeon. At these follow-
up visits, the treating orthopaedic surgeon performed a physical examination
of the knee, completed the surgeon part of the KSCRS, checked for adverse
events and changes in NSAID and other analgesic use.
During the treatment and follow-up period, the patients were allowed to use
only Acetaminophen (Paracetamol; maximum of 4 g/day). For patients strat-
iﬁed into the NSAID group, additional NSAID use was permitted. However, all
patients were asked to stop all analgesics at least 1 week before completing
the questionnaires and visiting their treating orthopaedic surgeon.STUDY OUTCOMESFor the WOMAC, the KOOS sub-domains [pain, stiffness, function, sport
and Quality of Life (QoL)] and the KSCRS, a higher score represented
Fig. 1. An overview of enrolment of the patients.
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(best score). In contrast, for the VAS for pain, 0 indicated no pain and 100
most severe pain. An absolute increase in the response rate of 30% on
the WOMAC scale, as compared to the rate in the placebo treatment was
considered a clinically relevant effect. With an expected standard deviation
of 40%, as frequently found in other OA treatment studies, 100 patients
were required to obtained a power of 90%.
Treatment failures were deﬁned as follows: patients who underwent a dif-
ferent treatment of the afﬂicted knee during the 12 months follow-up period;
patients randomized in the non-NSAID group who started NSAIDs during the
follow-up period; patients randomized in the NSAID group who increased
use of NSAIDs.Table I
Baseline demographic and clinical parameters. Baseline values of
both treatment groups were comparable.
Orthokin, n ¼ 80 Placebo, n ¼ 73
n % n %
Male 49 61 43 59
Analgesic medication use 22 28 24 33
PCM 12 15 17 23
NSAID 7 9 6 8
Other analgesics 3 4 1 1
Mean SD Mean SD
Age (years) 54 11 53 11
Weight (kg) 83 16 87 14
BMI (kg/m2) 27 5 28 14
WOMAC 54 18 50 16
KOOS pain 47 16 45 15
KOOS activity daily life 55 18 51 17
KOOS symptoms 55 18 48 17
KOOS sport 25 19 21 15
KOOS QoL 29 14 26 14
VAS for pain 60 20 63 18
KSCRS, patient part 69 23 68 20
KSCRS, Surgeon part 47 16 47 13STATISTICAL ANALYSISFileMaker Pro 6.0 for Windows (Filemaker Inc, Santa Clara, CA, USA)
and SPSS 12.0 for Windows (SPSS Inc., Chicago, IL, USA) were used for
data management and statistical analysis.
For comparison of the efﬁcacy of Orthokin vs placebo treatment, a re-
peated measure analysis was performed. When multivariate analysis
showed an interaction between the treatment effect and time, an additional
repeated measure analysis was performed in order to study the early (0e3
months) and late (6, 9, and 12 months) treatment effects. Although, random-
ization was stratiﬁed for NSAID usage, gender and age (<45 and >45 years
old), sub-analysis was performed for these groups. Finally, correlation anal-
ysis has been performed to study whether baseline characteristics, such as
age, gender, and degree of symptoms, could predict the outcome of the
treatment. Patients who were considered treatment failures, were excluded
for further follow-up. The data sets of these participants were completed
using the last-observation-carried-forward method. Statistical analysis of
treatment failure frequency between groups was separately done using the
Chi-square test. P-values less than 0.05 were considered statistically signif-
icant. All graphs show mean values with standard error of mean (S.E.M.).ResultsDEMOGRAPHICS AND BASELINE CHARACTERISTICSA total of 250 patients were screened for possible inclu-
sion into the study. Sixty-eight patients were excluded be-
cause they did not meet the inclusion/exclusion criteria or
voluntarily withdrew after receiving written and oral informa-
tion. One hundred and eighty-two met the inclusion and
exclusion criteria and were randomized to receive Orthokin
(n ¼ 94) or placebo (n ¼ 88). Before injection, six patients
were excluded and nine patients withdrew informed consent
(Fig. 1). Of the remaining 167 patients, 89 patients were
randomized to the Orthokin group and 78 were randomized
to the placebo group. Subsequently, 14 patients were
excluded from further analysis, because of serious adverse
events and major protocol violations (Fig. 1), i.e., 153
patients were analysed: 80 patients received Orthokin treat-
ment and 73 patients received placebo treatment.
Table II
Outcome scores per treatment over time. Values are given for the complete data set (all patients) and for the data set after stratification to
NSAID use during the trial. Note the fact that Orthokin-treated patients score consistently better at most data points suggesting a beneficial
biological effect of Orthokin
WOMAC KSCRS patient part KSCRS Surgeon part VAS
All patients (n ¼ 153)
Orthokin Mean SD Mean SD Mean SD Mean SD
Baseline 54.49 17.6 47.43 16.4 68.98 22.8 59.68 20.2
3 months 63.37 20.6 58.87 19.8 76.53 22.9 43.63 26.5
6 months 62.90 23.7 58.29 21.2 74.81 21.2 48.59 28.5
9 months 61.78 23.4 58.46 21.1 75.52 21.9 48.91 27.7
12 months 65.02 24.1 58.96 20.2 77.17 21.6 47.32 28.0
Placebo Mean SD Mean SD Mean SD Mean SD
Baseline 50.47 15.6 47.20 12.7 67.66 20.4 63.44 18.2
3 months 59.51 19.6 54.84 19.3 74.13 19.2 47.51 26.5
6 months 60.00 21.6 55.03 19.3 72.86 20.4 49.06 27.4
9 months 59.08 22.2 53.04 20.0 72.27 21.4 50.79 25.4
12 months 57.26 22.3 55.20 18.8 70.76 23.5 49.76 26.7
Non-NSAID using patients (n ¼ 140)
Orthokin Mean SD Mean SD Mean SD Mean SD
Baseline 55.14 17.8 69.03 23.2 47.84 16.4 59.88 20.7
3 months 65.32 20.5 76.86 23.0 58.65 19.6 47.23 26.7
6 months 62.77 23.6 75.05 21.4 58.05 21.4 49.21 28.5
9 months 61.53 23.3 75.99 21.7 58.28 20.9 50.03 27.2
12 months 65.57 23.7 77.85 21.1 59.12 20.1 47.79 27.8
Placebo Mean SD Mean SD Mean SD Mean SD
Baseline 50.75 15.9 67.66 20.9 47.93 12.6 62.61 18.7
3 months 59.90 19.2 75.03 19.1 55.57 19.1 46.14 26.5
6 months 61.05 21.4 74.44 20.3 56.12 19.3 47.66 27.7
9 months 60.31 22.5 73.91 21.4 54.19 20.2 49.38 25.9
12 months 58.49 22.6 72.47 23.4 56.79 18.3 48.45 27.0
NSAID using patients (n ¼ 13)
Orthokin Mean SD Mean SD Mean SD Mean SD
Baseline 47.77 14.6 68.43 19.6 43.21 16.6 59.71 15.3
3 months 65.92 22.7 73.14 23.0 61.16 23.0 40.57 25.6
6 months 64.29 26.3 72.29 20.8 60.90 21.5 42.29 29.8
9 months 64.29 26.2 70.71 24.4 60.09 24.8 37.43 32.4
12 months 59.52 29.1 70.29 27.3 57.10 24.0 42.57 31.0
Placebo Mean SD Mean SD Mean SD Mean SD
Baseline 47.40 12.4 67.67 13.7 36.92 9.5 72.67 7.3
3 months 55.21 24.9 64.33 18.1 47.38 21.3 62.33 24.1
6 months 48.78 21.8 56.17 12.5 44.48 16.2 64.00 20.9
9 months 45.49 13.7 54.50 12.7 41.38 13.3 66.33 12.5
12 months 43.92 14.5 52.50 15.8 36.15 15.4 64.00 18.7
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group were comparable (Table I), no signiﬁcant differences
between the treatment groups were found with respect to
age, gender, weight, body mass index (BMI) or use of
NSAIDs before and during the study period.TREATMENT EFFECTBoth Orthokin and placebo-treated patients showed a sig-
niﬁcant improvement on all outcome measures (P < 0.001),
as compared to baseline values. Comparable improve-
ments were found for the Orthokin and placebo treatment
on the WOMAC [28% vs 23% at 3 months, 15% vs 18%
at 6 months, 14% vs 17% at 9 months, and 19% vs 13%
after 12 months; n.s.; Table II, Figs. 2(A) and 3(A)]. On all
outcome parameters, Orthokin-treated patients scoredconsistently better as compared to placebo-treated patients.
However, the differences between the two treatment groups
were small. With respect to improvement over time, Ortho-
kin resulted in signiﬁcantly more improvement for KOOS
symptomatology (P ¼ 0.002) and KOOS sport (P ¼
0.042), as compared to placebo treatment [Fig. 2(C) and
(D)]. This coincides with the clinical observation that pa-
tients describe an initial effect on pain and subsequently
choose for an increase in activities in daily life (ADL), in
sports and in hobby. Furthermore, Orthokin-treated patients
consistently showed higher relative improvements com-
pared to placebo-treated patients for all other outcome pa-
rameters, except for the VAS at 3 months (21% vs 25%),
the KOOS sport at 3 and 9 months (41% vs 43%, and
42% vs 43%, respectively), and the KOOS ADL at 6 and
9 months (15% vs 17%, and 13% vs 16%, respectively),
Fig. 2. These graphs show the effect of Orthokin and placebo treatment over time on separate KOOS items. (A) WOMAC, (B) KOOS pain, (C)
KOOS symptomatology, and (D) KOOS sport. Bars represent mean  S.E.M.
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icant. Treatment failures were equally distributed over both
treatment groups (Orthokin 8, placebo 7; chi-square: P ¼
0.954), and were mainly due to worsening of symptoms
for which these patients were treated either with NSAIDs
or by surgical intervention.
Sub-analysis for age (<45 and >45 years old) and gen-
der did not show statistically signiﬁcant differences in re-
sponsiveness between these subgroups. In addition,
correlation analysis did not show signiﬁcant relations be-
tween baseline patient characteristics (age, gender, symp-
tom severity) and treatment outcome. Interestingly, the
superior improvement resulting from Orthokin treatment,
as compared to placebo treatment, appeared even more
pronounced upon sub-analysis for the patients who contin-
ued using NSAIDs during the trial (Fig. 3 and Table II). For
these patients (n ¼ 15), repeated measure analysis showed
that Orthokin treatment resulted in statistically signiﬁcant
more improvement of the KOOS sport parameters as com-
pared to placebo treatment (P ¼ 0.011; Fig. 3C). Further-
more, Orthokin resulted in signiﬁcantly more improvement
of the KSCRS, surgeons part: as compared to placebo
treatment (P ¼ 0.005; Table II).ADVERSE EVENTSDuring the trial, 219 adverse events were reported
(Table III). One hundred and ﬁfty-nine adverse events
were knee related, of which the majority was attributableto (subjective) increase of knee pain (Orthokin: 44 vs Pla-
cebo: 50; n.s.). The involved surgeons graded two adverse
events as serious; both cases were Orthokin-treated pa-
tients. The ﬁrst serious adverse event was due to a patient
with a septic arthritis of the knee joint. Because the product
was injected through a 0.22-mm sterile ﬁlter and because no
bacterial contamination was demonstrated by microbiologi-
cal testing of the sample, it was concluded that this event
was caused by the injection procedure and not by contam-
ination of the product. The second adverse event was re-
lated to a patient with repeated severe inﬂammatory
reactions of the knee joint within hours after the injection,
as reﬂected by severe pain, swelling, and warmth of his
knee joint. As a result, this patient discontinued the treat-
ment after three injections.
Discussion
Due to its high prevalence (6e12%of the adult population),
OA is associated with high cost for society induced by health-
care consumption and lost of productivity at work29,30. These
costs are expected to increase even more due to the ageing
of the population. Therefore, over the last decades, an
increasing interest for drugs that may alter the course of
OA development (DMOADs) and thereby possibly delaying
or even prevent the need for surgical interventions, such
as total joint replacement has developed. Orthokin is an
autologous blood product in which the production of various
anti-inﬂammatory cytokines, such as IL-1ra, have been
Fig. 3. These graphs show the effect of Orthokin and placebo treatment over time on separate KOOS items subdivided for NSAIDs (þNSAID)
and the non-NSAID (NSAID) strata. (A) WOMAC, (B) KOOS pain, (C) KOOS symptomatology, and (D) KOOS sport. Bars represent mean 
S.E.M., * indicated statistically signiﬁcant difference between groups.
503Osteoarthritis and Cartilage Vol. 16, No. 4demonstrated to be upregulated28. By competitive inhibition
of IL-1b in OA knee joints, this product may have a beneﬁcial
effect on the development of degenerative articular changes.
The aim of the current study was to evaluate the efﬁcacy
of Orthokin for treatment of knee OA in a randomized, multi-
centre, double-blind, placebo-controlled trial with a primary
efﬁcacy objective to demonstrate 30% superiority of the
Orthokin treatment on the WOMAC OA index at 3, 6, 9,
and 12 months post-treatment, as compared to placebo
treatment. In the current trial this objective was not met,
as the WOMAC showed comparable improvement ratios
for Orthokin and placebo treatment. However, absolute
values of the WOMAC and most other outcome measures
showed that Orthokin-treated patients scored consistently
better, compared to placebo-treated patients. In addition,
Orthokin treatment was found to result in statistically signif-
icant more improvement on the KOOS symptomatology
scores and the KOOS sport parameters. Altogether, these
ﬁndings suggest a beneﬁcial biological effect of Orthokin
on clinical symptoms arising from knee OA.
This hypothesis is further supported by the data set of pa-
tients who continued NSAID use during the trial (NSAID
group), in which Orthokin treatment resulted in even more
apparent improvement of the KOOS sport parameter and,
in addition, induced an improved knee function as measured
by the surgeon on the KSCRS. Furthermore, whencomparing the absolute values of the NSAID and the non-
NSAID group, a striking trend was observed, namely that pa-
tients who were treated with Orthokin in combination with
NSAIDs showed improvement similar to or more than both
Orthokin and placebo-treated patients of the non-NSAID
group. In contrast, for the placebo-treated patients of the
NSAID group, improvements were much smaller, or not ob-
served at all. This may be explained by the fact that all pa-
tients were required to stop all analgesics, including
NSAIDs, 1 week before completing the questionnaires and
visiting their treating surgeon. Patients using NSAIDs expe-
rienced more pain during this week than those not requiring
NSAIDs, an effect that was not seen in the NSAID group
treated with Orthokin. The absence of this trend for Ortho-
kin-treated patients is at least interesting, as this ﬁnding sup-
ports the hypothesis that Orthokin induces a beneﬁcial
biological effect.
Despite these ﬁndings, incorporation of Orthokin to the
standard spectrum of treatment modalities for symptomatic
knee OA needs careful consideration. The clinical beneﬁt
found in the current study was small and did not meet the
initial trial objective of 30% superiority on the WOMAC.
This may be due to several causes.
Based on the WOMAC outcome scores, the placebo effect
found in the current study was high, but comparable to other
studies studying the efﬁcacy of various oral and intra-articular
Table III
An overview of all adverse events registered during the trial. Prev-
alences of adverse events were compared using the chi-square
test. No statistically significant differences were found, except for
back pain
Orthokin,
n ¼ 80
Placebo,
n ¼ 73
Knee related adverse events
Pain during injection 10 8
Irritation after injection 70 67
Increase knee pain 44 50
Septic arthritis 1 0
Severe inﬂammatory arthritis
(non-septic)
1 0
Foreign body sensation 0 2
Crepitations 1 1
Locking 1 3
Irritation/pain 3 3
Swelling/synovitis 10 3
Redness/warmth 3 1
Stiffness 2 1
Muscle cramps 2 3
Heavy feeling 1 0
Injection in wrong (contra-lateral)
knee joint
1 0
Baker’s cyst 1 0
Meniscus degeneration 1 0
Ligament ruptures (ACL/MCL) 1 1
Other musculoskeletal adverse events
Foot pain 1 1
Back pain (P ¼ 0.009) 0 6
Hip pain 2 1
Shoulder pain/cuff tendonitis 2 1
Achilles tendon swelling 0 1
Stiffness of other joints 0 1
Hotspot at cuboid e metatarsal 5 joint 0 1
Heel pain 0 1
Fall on knee/knee distortion 9 5
Contra-lateral knee injury 4 1
General adverse events
Flu 4 1
Pneumonia 1 0
Jaw/molar inﬂammation 1 1
Infection 1 1
Headache/migraine 2 1
Nephrolithiasis 2 0
Groin pain 1 0
Hysteroscopy 1 0
Endometrium polyp 1 0
Hypertension 0 1
Admission to rehabilitation clinic 1 0
Hospital admission due 1 0
Weight reduction 0 1
Weight increase 0 1
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validity of the current data set11,31e33. However, demon-
strating a beneﬁcial effect of new treatment modalities is ham-
pered by such large placebo effects. Furthermore, it was
recently demonstrated that the patients’ perception of ones
health status and their symptoms of OA changes over time34.
This phenomenon can have a signiﬁcant impact on evalu-
ating the effectiveness of interventions, which is known as re-
sponse shift. This aspect is not taken into account in the
current study, which has been demonstrated to increase
the risk of a type-2 error34,35. On the other hand, it may be
argued that the treatment dose was to low, i.e., the smallOrthokin volume. However, the treatment was performed
strictly according to the manufacturer’s instructions. Further-
more, assuming that IL-1ra is the main effective mediator of
the Orthokin treatment, 2 ml of Orthokin provides sufﬁcient
IL-1ra intra-articularly in order to provide complete inhibition
of IL-1b28,36e39. Finally, asOA is a slowly progressive degen-
erative disease with gradually evolving symptomatology,
most OA patients are used to a certain degree of pain. As a
result, these patients may increase their activity rate until
an acceptable degree of complaints is reached, thereby dem-
onstrating improvement on activity scales (KOOS sport), but
suppressing improvements on all other scales.
Altogether, autologous induced synthesis of anti-inﬂam-
matory cytokines seems an interesting and possibly effective
approach in the treatment of symptomatic knee OA. How-
ever, Orthokin is based on human serum and therefore,
the quality of the product may be variable among different
patients. Also, apart from the upregulation of IL-1ra, IL-4,
IL-10, and IL-13, the modulation of numerous other proteins
by the incubation of blood with CrSO4-coated glass beads
has not been clariﬁed. Furthermore, the clinical relevance
of the demonstrated differences is disputable. Other,
cheaper, less invasive, and effective treatments, such as
NSAIDs and COX-2 inhibitors, are available for reducing
symptoms from knee OA5,6,40. In addition, results from re-
cent in vitro studies suggest that selective COX-2 inhibitors,
such as Celecoxib, may be an effective DMOAD41,42. Never-
theless, speciﬁcally the chondroprotective effect of Orthokin
on articular cartilage was not studied in the current trial, while
potentially being the most important aspect of this treatment.
However, the follow-up period of the current trial was to short
to reasonably expect a detectable protective effect on knee
radiographs. Therefore, we are in the process of to determin-
ing the chondroprotective effect of Orthokin by analysis of
knee radiographs after an extended follow-up period, and,
in addition, by determining cartilage breakdown products,
and pro- and anti-inﬂammatory cytokines in synovial ﬂuid
samples from this patient cohort.
Furthermore, cartilage defects have been demonstrated
to result in a disturbed joint homeostasis, which negatively
affects the outcome of cartilage tissue engineering tech-
niques43,44. As cartilage defects can lead to the develop-
ment of OA45,46, the disturbed joint homeostasis induced
by cartilage defects may very well occur through similar
pathways as those responsible for OA development. There-
fore, Orthokin may provide a feasible approach for further
optimization of cartilage tissue engineering techniques,
such as autologous chondrocyte implantation, although
this hypothesis remains to be studied in future clinical trials.
In conclusion, Orthokin appears to have a beneﬁcial bio-
logical effect on patient documented symptoms arising from
knee OA and warrant future investigations into the possible
chondroprotective effect, although the improvement in
symptomatology seems not clinically relevant.References
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